Lupus
Md Yuzaiful Md Yusof Yuz6Yusof
4 years 4 months ago
We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O
Dr. John Cush RheumNow
4 years 4 months ago
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg
Dr. John Cush RheumNow
4 years 4 months ago
Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021
On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab.
https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr
Eric Dein ejdein1
4 years 4 months ago
#EULAR2021. OP0293: Best disease activity measure for SLE flares?
⭐️c-SFI and SLE-DAS had best performance
⭐️SLE-DAS: easy to use for daily practice
@RheumNow https://t.co/9LJfbYxqOs
Andy Vermaut AndyVermaut
4 years 4 months ago
BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares https://t.co/dUJMKFkZ52 https://t.co/oAgKcGbW0k
Eric Dein ejdein1
4 years 4 months ago
#Eular2021 OP0289:
⭐️Remission off-Rx: SLEDAI=0 (minus serol), no IS
⭐️Remission on-Rx: SLEDAI 0, Pred<5mg, maintenance IS
⭐️LDAS: SLEDAI<=2 wo pred or IS
⭐️LLDAS: SLEDAI <=4, no maj organ, no new features, pred <=7.5+main
These states have ⬇️ damage accrual, rec'd T2T
@Rhuemnow
On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody
Dr. John Cush RheumNow
4 years 4 months ago
How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021
https://t.co/aVKY4B9CfW https://t.co/ffruCDouaE
Dr. John Cush RheumNow
4 years 4 months ago
#EULAR2021 Complex Immune Disturbances in ANA+ Individuals: Drs. Yusof and Hassan
https://t.co/nvSU7ArEUU https://t.co/7pJ5ypqDJn
Dr. John Cush RheumNow
4 years 4 months ago
Check out our Lupus content from #EULAR2021 at RheumNow.
https://t.co/Gmh4sFv4Jl https://t.co/yBkbeMn0Yd
Md Yuzaiful Md Yusof Yuz6Yusof
4 years 4 months ago
Does skin #lupus respond differently to rituximab?Dr Carter @LucyCarter6 reported 75% cutaneous response rate but overall non-response to tx was caused by skin domain. Interestingly, resistant skin post-tx was associated with low baseline #IFN scores #EULAR2021 #OP0134 @RheumNow https://t.co/JdtwdwNR4Z
Janet Pope Janetbirdope
4 years 4 months ago
AVN in SLE is ⬇️ing over time! risks are same: younger, male, glucocorticoids & also found hyperlipidemia. ?due to older age of onset & less steroids over time & better immune suppressants POS0730 @RheumNow #EULAR2021 @eular_org https://t.co/IG3NVrZl4D
Md Yuzaiful Md Yusof Yuz6Yusof
4 years 4 months ago
Once approved, what type of patients with #SLE would you treat with #anifrolumab? #EULAR2021 #OP0131 @RheumNow
Poster Hall